Blau Farmacêutica S.A. (BVMF:BLAU3)

Blau Farmacêutica Balance Sheet

Financials in millions BRL. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	46.77	45.6	33.32	31.5	14.11	51.86
Short-Term Investments	838.1	-	-	375.82	629.53	870.96
Trading Asset Securities	-	569.49	459.56	-	-	-
Cash & Short-Term Investments	884.87	615.09	492.87	407.31	643.65	922.82
Cash Growth	197.01%	24.80%	21.00%	-36.72%	-30.25%	330.52%
Accounts Receivable	515.33	458.47	476.75	453.56	420.61	331.79
Other Receivables	104.11	129.54	42.5	64.35	44.58	13.66
Receivables	619.44	588.02	519.25	517.91	465.19	345.45
Inventory	648.68	694.13	606.19	628.65	569.02	416.85
Other Current Assets	0.07	-	57.85	-	-	11.35
Total Current Assets	2,153	1,897	1,676	1,554	1,678	1,696
Property, Plant & Equipment	1,007	997.08	829.04	738.71	542.48	371.58
Long-Term Investments	-	-	265.16	265.19	-	0.04
Goodwill	-	151.66	151.66	151.66	143.24	143.24
Other Intangible Assets	708.41	67.86	53.81	24.83	16.57	5.75
Long-Term Deferred Tax Assets	73.23	77.8	84.52	81.53	-	-
Long-Term Deferred Charges	-	397.6	282.28	177.58	74.25	49.82
Other Long-Term Assets	85.12	45.81	69.12	60.17	44.65	61.14
Total Assets	4,027	3,635	3,412	3,054	2,499	2,328

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	256.78	266.38	286	179.92	163.64	116.43
Accrued Expenses	104.2	89.21	90.21	55.62	56.78	55.2
Short-Term Debt	56.09	94.49	1.87	2.3	-	41.73
Current Portion of Long-Term Debt	181.65	184.03	65.1	67.92	79.87	49.82
Current Portion of Leases	6.72	7.07	6.39	4.8	3.67	2.11
Current Income Taxes Payable	11.79	0.03	8.92	-	19.44	19.99
Other Current Liabilities	50.18	127.24	79.46	25.38	47.71	57.72
Total Current Liabilities	667.41	768.45	537.94	335.93	371.11	343.01
Long-Term Debt	583.33	283.33	450	500	200	272.5
Long-Term Leases	25.3	30.21	35.59	33.52	28.17	8.35
Long-Term Deferred Tax Liabilities	232.49	221.98	170.2	125.64	35.02	18.25
Other Long-Term Liabilities	201.64	75.32	67.33	63.2	46.81	51.05
Total Liabilities	1,710	1,379	1,261	1,058	681.11	693.16

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	1,717	1,717	1,317	1,317	1,317	1,317
Retained Earnings	670.44	612.28	899.32	744.37	562.8	325.13
Treasury Stock	-42.89	-42.89	-42.89	-42.89	-39.9	-
Comprehensive Income & Other	-10.21	-14.23	-9.05	-16.62	-17.36	-5.45
Total Common Equity	2,334	2,272	2,164	2,001	1,822	1,636
Minority Interest	-17.61	-16.02	-13.33	-6.22	-4.22	-1.4
Shareholders' Equity	2,316	2,256	2,151	1,995	1,818	1,635
Total Liabilities & Equity	4,027	3,635	3,412	3,054	2,499	2,328

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	853.09	599.13	558.95	608.54	311.71	374.52
Net Cash (Debt)	31.78	15.95	-66.08	-201.22	331.93	548.3
Net Cash Growth	-	-	-	-	-39.46%	-
Net Cash Per Share	-	0.07	-0.29	-0.87	1.44	2.35
Filing Date Shares Outstanding	-	230.98	230.98	230.98	231.18	233.21
Total Common Shares Outstanding	-	230.98	230.98	230.98	231.18	233.21
Working Capital	1,486	1,129	1,138	1,218	1,307	1,353
Book Value Per Share	-	9.84	9.37	8.66	7.88	7.02
Tangible Book Value	1,626	2,052	1,959	1,825	1,662	1,487
Tangible Book Value Per Share	-	8.88	8.48	7.90	7.19	6.38
Machinery	-	440.23	338.57	302.14	170.92	135.22
Construction In Progress	-	335.21	296.26	257.03	210.19	194.06

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 18, 2026

Data Sources Report a data error